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Deciphering the complex network structure is crucial in drug target identiﬁcation. This study presents a
framework incorporating graph theoretic and network decomposition methods to analyze system-level
properties of the comprehensive map of the epidermal growth factor receptor (EGFR) signaling, which
is a good candidate model system to study the general mechanisms of signal transduction. The graph the-
oretic analysis of the EGFR network indicates that it has small-world characteristics with scale-free topol-
ogy. The employment of network decomposition analysis enlightened the system-level properties, such
as network cross-talk, speciﬁc molecules in each pathway and participation of molecules in the network.
Participating in a signiﬁcant fraction of the fundamental paths connecting the ligands to the phenotypes,
cofactor GTP and complex Gb/Gc were identiﬁed as ‘‘housekeeping” molecules, through which all path-
ways of EGFR network are cross-talking. c-Src–Shc complex is identiﬁed as important due to its role in all
fundamental paths through tumorigenesis and being speciﬁc to this phenotype. Inhibitors of this com-
plex may be good anti-cancer agents having very little or no effect on other phenotypes.
 2008 Elsevier Inc. All rights reserved.1. Introduction
Mammalian cells integrate information from complex intracel-
lular signal transduction pathways to make decisions in response
to changes in the environment. Signaling molecules and their net-
works play important roles in molecular diagnosis and therapy of
diseases as almost all known diseases exhibit some kind of dys-
function at transcriptional level. There has been a great deal of
enthusiasm to identify novel drug targets based on knowledge of
key signal transduction components which have links to diseases.
Elucidating cellular signaling is central for gaining insight into
the molecular mechanisms behind diseases as well as adaptation
of living cells to changes in the environment. In recent years the
high-throughput techniques such as transcriptomics, proteomics
and metabolomics enabled the collection of genome scale experi-
mental data and lead to the reconstruction of large-scale signaling
networks [1–3].
A very important signaling mechanism in mammalian cells is
the epidermal growth factor receptor (EGFR) signaling which reg-
ulates processes such as growth, survival, proliferation and differ-
entiation. The malfunctions in this signal transduction network
may lead to uncontrolled cell proliferation resulting in tumorll rights reserved.
rmus Tekir).
Marmara University, 34722formations. It may also cause diseases with immunological, inﬂam-
matory and degenerative syndromes [4]. Therefore the unraveling
of EGFR signaling mechanism is vital for the identiﬁcation of
potential drug targets and also for understanding of design princi-
ples of signaling mechanisms in development and tissue homeo-
stasis [5,6]. The mechanism of the EGFR signaling has been
analyzed thoroughly both experimentally and computationally to
uncover the unknowns about general principles of signal transduc-
tion processes including receptor-mediated endocytosis, oncogen-
esis, mitogen-activated protein kinase (MAPK) signaling pathways,
multi-receptor family interactions, autocrine loops and receptor
transactivation [7]. Although lots of computational models have
been developed for the EGFR signaling system [8–19] only a lim-
ited part of the system was modeled before Oda and coworkers’
work [2] in which the most comprehensive pathway map for
EGFR-induced and related pathways was published. It has the
overall bow-tie structure that is a characteristic of the robust
evolvable systems [20]. This structure implies that a variety of
ligands bind to corresponding receptors, leading to diverse
phenotypes via activations of the intermediate signaling molecules
in the network [2]. Small-scale models were used as the basis for a
dynamic analysis of EGFR signaling with determined kinetic
parameters [15,19,21,22]. Large-scale stoichiometric models, on
the other hand, give information on the architectural feature of
the signaling network [2].
The structure-oriented analyses usually provide valuable
insight into the mechanisms of the networks by deﬁning
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sis of metabolic networks is a well-established ﬁeld, relatively
few methods have been proposed so far to analyze structural
properties of interaction and signaling networks [24]. In the last
decade, methods derived from graph theory have been devel-
oped to understand the structure of the systems of molecular
interactions [25,26]. In this study, the graph theoretic analysis
was performed to detect the components that are well or poorly
connected in the interaction network and thus it may be a useful
guide for experimental studies on protein interactions. Moreover,
time-invariant topological structure of the network were decom-
posed into a system of linear paths [27,28] connecting ligands to
each phenotype. The signaling molecules involved in the linear
paths and the path lengths provided system-level information
on the signaling network allowing us to observe network
cross-talk (shared molecules in linear paths leading to diverse
phenotypes), molecules speciﬁc to each phenotype and participa-
tion of molecules in signaling pathways. Using all these informa-
tion, one may identify drug targets for cancer by inhibiting
molecules involved in linear paths leading to tumor formation
or by inducing molecules involved in linear paths going to
apoptosis.2. Materials and methods
2.1. The map of EGFR-mediated signaling network
The map of EGFR signaling network [2] analyzed here consists
of EGFR endocytosis with its degradation or recycling, small gua-
nosine triphosphatase (GTPase)-mediated signal transductionFig. 1. Simpliﬁed version of thesuch as mitogen-activated protein kinase (MAPK) cascade, phos-
phatidylinositol polyphosphate (PIP) signaling, cell cycle, and G
protein-coupled receptor (GPCR)-mediated EGFR transactivation
via intracellular Ca2+ signaling (a simpliﬁed but descriptive ver-
sion of the map of [2] is given as Fig. 1). This map is a state
transition diagram in which one state of the system constituents
is represented as a species and the transition from one state to
another (by enzymatic modiﬁcation, association, dissociation
and translocation) is represented as a reaction. When there
exists more than one state of a compound each state (e.g. phos-
phorylated and unphosphorylated) are considered as different
species to be able to represent the state transitions as reactions.
The map was constructed by Oda and coworkers manually based
on EGFR signaling papers using the software CellDesigner
(http://celldesigner.org/) where the interactions in the network
were stored in Systems Biology Markup Language (SBML;
http://sbml.org/). The map includes 211 reactions (131 state
transitions, 34 transportations, 32 associations, 11 dissociations,
2 truncations, and 1 unknown transition) and 322 species (202
proteins, 3 ions, 21 simple molecules, 73 oligomers, 7 genes, 7
RNAs, 8 degraded products, and 1 unknown molecule). The EGFR
signaling network has a bow-tie structure having a variety of li-
gands (inputs) and phenotypes (outputs) that are connected to a
conserved core with redundant and cross-talking signaling path-
ways. Fifteen members of the endogenous EGF ligand family
(amphiregulin, betacellulin, biregulin, EGF, epiregulin, HB-EGF,
heregulin ab, neuregulin (NRG) 1a1b2a2b34, and transforming
growth factor alpha (TGFa) [29–31]) bind to their speciﬁc eryth-
roblastic leukemia viral (v-erb-b) oncogene homolog (ErbB) fam-
ily receptors, ErbB1 (EGFR), ErbB2, ErbB3, ErbB4 [31–33] to
activate signal transduction which produces physiological eventsEGFR signaling network [2].
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tion, cell cycle progression, transcriptional regulation of down-
stream genes, tumorigenesis (production of a tumor) and
mitogenesis (induction of mitosis) [2].
2.2. Graph theoretic analysis
The ﬁrst step in a graph theory based analysis is the mathemat-
ical representation of an interaction network as a graph where
nodes are signaling molecules and edges connecting nodes are
interactions. The second step is to determine graph properties of
the network using graph theoretic techniques. These properties
are the degree (connectivity) of nodes, the number of hubs (highly
connected nodes) and the shortest path lengths between indirectly
connected nodes [34]. Before the studies in the last decade
[25–26,35–41] complex networks were modeled using classical
random network theory [42,43] which assumes that nodes in the
network are connected with each other randomly with a probabil-
ity p. This theory results in random homogenous networks in
which k values (connectivity) show a Poisson distribution where
the peak is at <k> (average connectivity) and the probability of
ﬁnding a highly connected node decays exponentially (P(k)  ek
for k >> <k>). In fact biological networks are heterogeneous in nat-
ure and there are a few highly connected nodes (hubs) that link the
less connected nodes to the network (scale-free nature) following a
power law model (P(k)  kc) [25]. Biological networks also have
small-world architectures with relatively short paths between
any two nodes despite their large sizes [38].
In our work, the graph properties were determined using the
algorithm of Arga and coworkers [28] implemented in MATLAB
7.0. The input to the algorithm is the adjacency matrix (S), which
is a binary, square matrix representing the edges between nodes.
S(i,j) = 1, if (i,j) is an interacting molecule pair, otherwise S(i,j) = 0.
The state transition diagram of EGFR signaling network is repre-
sented by this adjacency matrix where the molecules in a reaction
are considered as interacting pairs. The element of the nth power of
the adjacency matrix, Sn(i,j), gives the number of paths with path
length of n from molecule i to molecule j. During the calculation
of successive powers of the adjacency matrix, the ﬁrst nonzero va-
lue of S(i,j) is the shortest path length between molecules i and j.
Mean path length and the diameter of the network are calculated
as the average and maximum of shortest path lengths, respectively.
2.3. Network decomposition analysis
Network decomposition analysis includes decomposition of a
network into fundamental paths through linear combination of
which the time-invariant topological structure can be captured
[28]. It is shown to be useful to deﬁne the structure of the network
and the overall capabilities of the cell [44–49]. In this study, among
the various decomposition techniques, linear path analysis was
chosen for the structural investigation of the EGFR signaling net-
work since the number of fundamental routes for small-world,
large-scale networks such as EGFR signaling network [2] is very
high and computationally unmanageable with other pathway anal-
ysis methods reported in literature [27,44,47]. As opposed to ele-
mentary ﬂux modes [44,48,49] and extreme pathways [47], the
number of linear paths [27] connecting inputs to outputs of the
network can be limited by specifying the maximum path length
in the calculation procedure.
In order to investigate the topology of the EGFR signaling net-
work, linear paths connecting ligands to phenotypes were deter-
mined using NetSearch algorithm [27]. The EGFR signaling map
[2] was converted into a protein–protein interaction graph by
using directed interactions between reactants-products and modi-
ﬁers-products of the same reaction (the direction is always to-wards the products of the reactions) regardless of whether
modiﬁer-product interaction describes an activation or deactiva-
tion (see Supplementary material). This graph was then used as
the input to the NetSearch algorithm. In addition to this interaction
(connectivity) information, inputs (ligands) and outputs (pheno-
types as cellular responses) were deﬁned for the linear path calcu-
lations. The linear path analysis was performed to get information
about network cross-talk, speciﬁc molecules for each phenotype
and participation of signaling molecules in the pathways of the
EGFR signaling network.
The NetSearch algorithm [27] allows user to deﬁne the length of
the longest linear paths in the calculation procedure. We observed
that, the number of linear paths increases exponentially with max-
imum path length for all phenotypes. Using the following exponen-
tial relationship between the number of linear paths (n) and the
maximum path length (l),
n ¼ a  ebðllminÞ ð1Þ
we determined the exponential coefﬁcient, b, which is an indicator
of the complexity of the regulation of the phenotypes. Larger b
means more linear paths with the same path length, i.e. more alter-
native signaling routes. In Eq. (1), lmin is the minimum path length
giving at least one linear path for the corresponding phenotype, and
a is the number of linear paths at the minimum path length
(l = lmin).
Common (network cross-talk) and speciﬁc molecules were de-
ﬁned as identical molecules used in linear paths targeting diverse
phenotypes and molecules used in linear paths targeting only
one phenotype, respectively. Finally, molecule participation in
the network was considered as participation percentages of the
molecules in the linear paths of each phenotype.
2.4. Pathway logic
Pathway logic is an approach to model biological processes
based on rewriting logic (uses rewriting logic language Maude).
It allows modeling and symbolic analysis of signaling and meta-
bolic networks enabling the user to visualize the network in Petri
nets format [50]. This approach enables researchers to understand
complex biological systems by in silico experiments and accelerates
the design of in vivo experiments to test the ﬁndings. Using formal
methods tools of pathway logic, biological networks can be que-
ried. For a chosen initial condition, it shows all pathways leading
to a speciﬁed ﬁnal condition [51]. In this work, we tested the re-
sults of network decomposition analysis by pathway logic. The
EGFR network was implemented in Maude (http://maude.csl.sri.-
com) deﬁning species and reactions and, the network was queried
by the pathway logic assistant [50]. The critical molecules for each
phenotype found from network decomposition analysis were ana-
lyzed by deleting them and observing their effects on the corre-
sponding phenotypes.3. Results and discussion
3.1. Graph theoretic analysis
The EGFR signaling network [2] was represented by an undi-
rected interaction graph with 329 nodes and 1795 edges connect-
ing them. Using the algorithm [28] mentioned in Section 2.2, the
network diameter and the mean path length were calculated as
11 and 4.7, respectively. These results indicate that any two nodes
in the system can be connected by relatively short paths along
existing links despite of large size of the EGFR signaling network.
In other words, the EGFR-mediated signal transduction network
has small-world architecture that is a general feature of many
Fig. 2. Degree (connectivity) distribution of the nodes in the EGFR signaling
network.
Fig. 3. Shortest path lengths from ligands to the phenotypes in the EGFR signaling
network.
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signaling network may lead to shorter transition times between
different states [38]. Comparative analysis of graph theoretic prop-
erties of the EGFR network with those of other protein interaction
networks reported in literature (Table 1) indicates signiﬁcant sim-
ilarity especially between distance measures, i.e. mean path length
and network diameter. It was found that the connectivity (k, the
number of links per node) distribution of the nodes in the graph
has a scale-free nature (Fig. 2) following nearly a power law model
(P(k)  kc c = 1.86 with R2 = 0.84) which is a general characteris-
tics of biological networks [25,53] as well as World-Wide Web
[35,54], social networks [39] and scientiﬁc collaboration networks
[55]. The nodes in Fig. 2 were analyzed statistically by Essential
Regression ver. 2.2 and the small number of nodes having only
one link to the network was determined as an outlier point and
therefore excluded in the inner diagram of Fig. 2. The hubs in
EGFR-mediated signaling network were found as the complex of
ErbB1 ligand-active EGFR, the co-factors, GTP (guanosine triphos-
phate) and GDP (guanosine diphosphate), and Gb/Gc (b/c subunits
of the heterotrimeric G-protein) having 36, 31, 31 and 29 connec-
tivities, respectively. GTP, GDP and Gb/Gc are involved in GPCR (G
protein-coupled receptor)-mediated EGFR transactivation. This re-
sult is in agreement with the literature information that the GPCRs
are involved in all types of signaling pathways. Therefore their
malfunctions cause many pathological conditions and now the
GPCRs are targets of 40–50% of all modern medicinal drugs [56].
3.2. Linear paths of the bow-tie structured EGFR network
The molecular interactions of a network can be used for a sys-
temic analysis of input/output relationships via linear paths start-
ing from ligands ending at phenotypes. The NetSearch algorithm
[27] gives the number of linear paths with their length (the num-
ber of interactions in each path). For the phenotypes of tumorigen-
esis and mitogenesis, all steps in the network are same except the
last one going towards the corresponding end-phenotypes. Hence
in network decomposition analysis of the EGFR network, tumori-
genesis and mitogenesis were considered as one phenotype
(tumorigenesis–mitogenesis) throughout this study.
The shortest path lengths were calculated for each phenotype
(Fig. 3). The maximum of the shortest path lengths was found as
14 which give the network diameter for the phenotypes in the
EGFR signaling network, i.e. in 14 molecular interactions (state
transitions) the ligands can be linked to all phenotypes through
signaling molecules. This value is higher than the network diame-
ter of 11 obtained from graph theoretic analysis (Section 3.1). TheTable 1
Graph theoretic properties of protein interaction networks
Model Number of nodes Number of interactions
EGFR [2] 329 1795
S. cerevisiae 2115 2240
S. cerevisiae 5253 65673
S. cerevisiae (signaling) 1363 3649
DIP (S. cerevisiae-Core) 2640 6600
DIP (S. cerevisiae) 4773 15444
MIPS (S. cerevisiae) 2043 5434
DIP (S. cerevisiae) 5798 20098
Uetz (S. cerevisiae) 1870 4480
Ito (S. cerevisiae) 3280 8868
Ito (S. cerevisiae-Core) 797 1560
DIP (D. melanogaster) 7451 22819
DIP (C. elegans) 2638 4030
DIP (H. pylori) 710 1420
DIP (H. sapiens) 1065 1369
DIP (E. coli) 553 761
DIP (M. musculus) 329 286difference in network diameters is due to the fact that the
adjacency matrix (input of the graph theoretic calculations) isMean degree Mean path length Diameter Reference
10.91 4.70 11 Present study
2.12 6.80 14 [53]
25.00 5.21 11 [28]
5.35 6.81 9 [28]
5.00 5.00 13 [111]
6.50 5.01 13 [111]
5.32 7.71 16 [112]
6.93 4.90 12 [112]
4.79 6.8 15 [112]
5.41 4.9 13 [112]
3.91 6.2 16 [112]
6.20 4.40 11 [111]
3.10 4.80 14 [111]
4.00 4.10 9 [111]
2.60 6.80 21 [111]
2.80 5.50 16 [111]
1.70 3.60 9 [111]
Table 2
Approximately same number of linear paths with different maximum path lengths for the phenotypes of the EGFR signaling network
Phenotype # of paths (100)—max path
length
# of paths (200)—max path
length
# of paths (500)—max path
length
# of paths (1000)—max path
length
Apoptosis 89–12 238–14 487–16 993–18
Cell cycle progression 74–18 248–20 598–22 961–23
Actin reorganization 91–11 212–15 479–19 980–21
Target genes
transcription
84–14 242–17 466–19 1027–22
Tumorigenesis–
Mitogenesis
118–18 225–20 498–23 1026–28
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algorithm) is directed.
In order to obtain information about the complexity of the reg-
ulation of the phenotypes by a comparative analysis among the
phenotypes, we obtained quantitative data by changing the maxi-
mum path lengths and observing the resultant number of linear
paths for each phenotype (Table 2). The exponential increase in
the number of linear paths with maximum path length for each
phenotype can be visualized when the results are plotted in
Fig. 4. Using Eq. (1) and the data in Table 2 exponential coefﬁcients
(b) were determined for each phenotype (Table 3). Owing to their
higher exponential coefﬁcients one can state that apoptosis and
cell cycle progression as cell responses of EGFR signaling have
more complex regulation mechanisms in EGFR signaling network.
In other words, the ﬂowing signal has more alternative routes
through these phenotypes. There are intimate links between cellu-
lar complexity and robustness which is the ability to maintain per-
formance in the face of perturbations [57]. This fact increases the
insensitivity of apoptosis and cell cycle progression against any
mutations in the signaling molecules having the larger b values.
Each day around 50–70 billion cells die in an average human adult,
and on a yearly basis apoptosis of this amount of cell correspondsFig. 4. Number of linear paths with maximum path lengths.
Table 3
Exponential coefﬁcients of Eq. (1)
Phenotype Exponential coefﬁcient (b) Fitness (R2)
Apoptosis 0.3976 0.9931
Cell cycle progression 0.5067 0.9941
Actin reorganization 0.2301 0.9887
Target genes transcription 0.3138 0.9945
Tumorigenesis–mitogenesis 0.2126 0.9656to the weight of an average human body [58]. On the other hand,
cell cycle response (cell-division cycle) being responsible for cellu-
lar differentiation during embryogenesis, morphogenesis and
maintenance of stem cells during adult life is also widespread in
nature [59].
3.2.1. Network cross-talk
The structure of the EGFR signaling network was captured as a
system of linear paths (2nd column of Table 2). In order to compre-
hensively analyze the reactions and molecules included in these
linear paths, the number of linear paths was constrained to around
200 since this amount of paths includes most of the molecules (at
least once) in the EGFR signaling network and hence is expected to
give statistically meaningful information about network cross-talk,
molecules speciﬁc to the phenotypes and molecule participation in
pathways discussions.
The linear paths of a network allow a quantitative evaluation of
network cross-talk by observing identical molecules involved in
linear paths leading to diverse responses. Various deﬁnitions and
measures of cross-talk have been described in the literature taking
into account structural and dynamic aspects [1,60–65]. Here, we
accept the classical deﬁnition in which sharing of identical signal-
ing molecules in different signaling pathways is used as a measure
of cross-talk [60]. It was observed that the cofactor GTP and the
complex Gb/Gc are involved in more than 70% of the linear paths
through all phenotypes in the network. All pathways leading to a
phenotype in the EGFR signaling network are cross-talking through
these signaling molecules. It can therefore be stated that these
molecules are crucial for the continuity of the signal transduction
as their deﬁciencies may prevent most of the linear paths for all
phenotypes to be completed. For each phenotype, the molecules
involved in more than 50% of the linear paths were consideredTable 4
Shared molecules of cross-talking pathways in the EGFR signaling network
Phenotypes Shared molecules
Apoptosis Abi1–Eps8–activeSOS1
Cell cycle progression Vav2–EGFR
Cdc42–Rac–GTP
Cdc42–Rac–GDP
Active MKK4
Protein p53
Target genes transcription c-Src
Tumorigenesis–mitogenesis
Actin reorganization IP3
Target genes transcription IP3R
Tumorigenesis–mitogenesis Phosphorylated IP3R
Ca+2 in cytosol
Ca+2 in ER
PYR
Apoptosis DAG
Cell cycle progression PLCc–EGFR
Tumorigenesis–mitogenesis
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pathways (i.e. cross-talking pathways) were analyzed for network
cross-talk (Table 4).
The complex Abi1 (Abl Interactor 1)—Eps8 (EGFR pathway sub-
strate 8)—SOS1 (Son of sevenless 1) is known to activate cytoskel-
etal changes [66]. In the EGFR network, it was found to be involved
in most of the linear paths going to apoptosis and cell cycle pro-
gression. It has role in 30% of the linear paths of the phenotype ac-
tin reorganization (cytoskeletal changes). Vav is activated by EGFR
and it acts as a guanine nucleotide exchange factor for Rac1 and
Cdc42 [67]. The complexes Abi1–Eps8–SOS1, Vav2–EGFR, Cdc42–
Rac–GTP and Cdc42–Rac–GDP are involved in linear paths of the
inhibiting route of cell cycle progression. The signal coming from
these complexes causes the transcriptional inhibition of p53 which
inhibits directly cell cycle progression. Additionally, these four
complexes are involved in both activating and inhibiting routes
through apoptosis. On the other hand, the investigation of the lin-
ear paths including active MKK4 indicates that it has roles in
inducing route towards apoptosis as well as inhibiting route to cell
cycle progression (like the above complexes, MKK4 is also on the
signaling path which inhibits the transcription of p53). p53 is
found to be involved in the linear paths activating cell death
through apoptosis in addition to the linear paths inhibiting cell
proliferation through cell cycle progression indicating its tumor
suppressor effect. It is known that MKK4 [68,69] and p53 [70–
72] have inhibitory roles in tumor growth in various cancer types.
In EGFR signaling network, the pathways ending with pheno-
types; target genes transcription, tumorigenesis and mitogenesis
are cross-talking via c-Src. Its tyrosine kinase activity has roles in
the growth of tumor cells [73,74]. c-Src complex with Pyk2 is in-
volved in most of the linear paths of target genes transcription
whereas the complex c-Src–Shc has roles in all linear paths going
to tumorigenesis and mitogenesis (Tables 5 and 6).
The calcium signaling molecules (IP3, IP3R, Ca+2, PYR) are
shared by the pathways of actin reorganization, tumorigenesis
and mitogenesis in the EGFR network. Calcium signaling is re-
quired for actin reorganization regulating intercellular adhesion
between ﬁbroblasts [75]. According to the results of our network
decomposition analysis, calcium signaling may be one of the mech-
anisms by which EGF mediates the growth of tumor cells as also
hypothesized [76].Table 5
Speciﬁc molecules of the phenotypes of the EGFR signaling network
Apoptosis Cell cycle progression
p38 MAPK c-Jun
Active p38 MAPK c-Jun at nucleus
Active MKK3 Dimer of c-Jun at nucleus
Active MKK6 JNK
Active JNK
Active MKK7
MEKK1–GTP–Rac1/Cdc42
MLK3–Rac1/Cdc42
PGE2–active EP2/4
Table 6
The top ﬁve molecules that participate in most of the linear paths of each phenotype in t
Apoptosis Cell cycle progression Actin reorganizat
GTP (84.5%) c-Jun (97.6%) GTP (92.0%)
Abi1–Eps8–active SOS1
(83.6%)
c-Jun at nucleus (97.6%) Gb/Gc (74.5%)
Vav2–EGFR (83.6%) Dimer of c-Jun at nucleus (97.6%) Active PLCb (70.3
Cdc42–Rac–GTP (83.6%) Protein p53 (97.6%) Active truncated P
Cdc42–Rac–GDP (83.6%) RNA p53 (97.6%) Ca+2 in cytosol (6Another combination of cross-talking phenotypes is apoptosis,
cell cycle progression, tumorigenesis and mitogenesis. The signal-
ing pathways through these phenotypes use DAG (diacylglycerol)
and PLCc (phospholipase Cc). DAG functions as a second messen-
ger signaling lipid that regulates cell growth and apoptosis and is
made by phospholipids [77,78]. It was also shown that DAG has
function in actin reorganization [79].
3.2.2. Speciﬁc molecules
Beyond the shared molecules in linear paths leading to different
phenotypes, speciﬁc (non-shared) molecules are also observed in
linear paths of each phenotype in the EGFR signaling network
(Table 5). These speciﬁc molecules are involved in more than 50%
of the linear paths of one phenotype, but have roles in less than
50% of the linear paths through other phenotypes. Interestingly, ac-
tin reorganization is the only phenotype with no speciﬁc molecule,
i.e. all of the molecules targeting this phenotype are also function-
ing in mechanisms targeting other phenotypes.
Apoptosis is an active form of cell death that eliminates dam-
aged cells in organisms [80]. Expectedly, molecules deﬁcient in
apoptotic pathway result in uncontrolled cell growth (tumor)
[58,81]. Several anti-cancer drugs induce apoptosis [82]. Activation
of p38 MAPK (mitogen-activated protein kinase) is associated with
induction of apoptosis [83]. It was shown that MKK3 and MKK6 are
essential for p38 MAPK activation [84].
The cell cycle progression or cell-division cycle is the series of
events in a eukaryotic cell until it replicates itself. c-Jun has been
deﬁned as a positive regulator of cell cycle progression (G1 to S
phase) [85]. It has been shown that JNK signaling to c-Jun is
required for cell proliferation with possible functions in S and
G2-M phases [86]. MKK7 is a direct activator of JNKs involved in
signaling in G2-M cell cycle progression [87]. It is known that
MEKK1 is important in regulating cell survival [88]. Silencing
MLK3 in mammalian cells inhibits cell proliferation of normal
and tumor cells possibly affecting regulators of cell cycle progres-
sion [89]. EP2 and 4 are receptors of PGE2 (prostaglandin E2)
which acts at all phases of the cell cycle to delay normal progres-
sion [90].
STAT3 (Signal Transducer and Activator of Transcription) was
found as one of the activators of the gene transcription phenotype
of EGFR signaling as its name implies. STAT3 is a target of the c-SrcTarget genes transcription Tumorigenesis–mitogenesis
STAT3 LPA–active LPA2
Active STAT3 PKC
STAT3 at nucleus Active PKC
Phosphorylated STAT3 Active PDK1
Pyk2 Active c-Src–Shc
Active Pyk2
Active c-Src–Pyk2
Grb2–EGFR–active Pyk2
he EGFR signaling network
ion Target genes transcription Tumorigenesis–mitogenesis
ErbB1 ligand-active EGFR
(88.0%)
ErbB1 ligand-active EGFR
(100%)
Active Pyk2 (79.3%) ATP (100%)
%) Grb2–EGFR-active Pyk2 (79.3%) KDI1 (100%)
LCb (70.3%) c-Src (79.3%) c-Src (100%)
7.9%) Active c-Src –Pyk2 (79.3%) Active c-Src–Shc (100%)
234 S. Durmus Tekir et al. / Journal of Biomedical Informatics 42 (2009) 228–236non-receptor tyrosine [91]. Pyk2 ampliﬁes c-Src induced STAT3
activation [92]. Grb2 (Growth factor receptor bound protein) is
essential for multiple cellular functions [93]. In this study, the
complex Grb2–EGFR–Pyk2 was found to be speciﬁc to target genes
transcription signaling pathway.
Tumorigenesis is the formation of tumor as a result of uncon-
trolled cell proliferation. Signaling molecules speciﬁc to this phe-
notype is so crucial to develop drugs for the treatment of cancer
since inhibition of these speciﬁc molecules does not signiﬁcantly
affect other phenotypes of the network. LPA (lysophosphatidic
acid) was shown to be involved in rapid tyrosine phosphorylation
of EGFR in tumor cells. It was proposed as a candidate tumor pro-
moter [94]. LPA–LPA2 (receptor of LPA) was found as speciﬁc to
tumorigenesis–mitogenesis phenotypes supporting the previous
ﬁndings. Similarly PKC (Protein Kinase C) was reported as mediat-
ing EGF-induced growth of head and neck tumor cells by regulat-
ing MAPK [95]. It is also known that inhibition of PDK1 is
effective in the treatment of cancer and tumors since it regulates
several oncogenic pathways [96–98]. The ﬁnal molecule speciﬁc
to tumorigenesis–mitogenesis is the complex c-Src–Shc which
has role in EGF-dependent cell cycle arrest and apoptosis in human
epidermoid carcinoma A431 cells [99]. From the network, it was
observed that this complex mediates the phosphorylation of ErbB1
ligand-active EGFR, and then the phosphorylated ligand–receptor
complex undergoes tumorigenesis or mitogenesis as also hypothe-
sized [100].
All speciﬁc molecules found from linear path analysis (Table 5)
were analyzed by pathway logic assistant [51]. These molecules
were deleted one by one and all possible pathways were searched
in the absence of deleted molecule targeting the relevant pheno-
type. The results are in parallel with the results of network
decomposition analysis, speciﬁc molecules affect mostly their cor-
responding phenotypes (leaving small number of paths through
phenotypes) having very little or no effects on other phenotypes.
3.2.3. Participation of molecules
The role of species in linear paths can be considered as an
indication of their importance in the signal transduction since
any state of the signaling network is a nonnegative combination
of the linear paths. One can therefore comment about the impor-
tance of each molecule for each phenotype by its participation
percentage in linear paths. The participation percentage of a
molecule is the percentage of the linear paths (given in 2nd col-
umn of Table 2) the molecule contributed in. The top ﬁve mole-
cules that participate in most of the linear paths of each
phenotype in the EGFR signaling network (Table 6) were tested
by pathway logic approach. The inhibitory effect of the mole-
cules that participate in most of the linear paths through each
phenotype, were observed in the resulting network when they
were blocked. For instance, deletion of the molecules with
100% participation in the linear paths through tumorigenesis
and mitogenesis (ErbB1 ligand-active EGFR, ATP, KDI, active
c-Src–Shc) from the system resulted in an empty set when the
network was targeted to these phenotypes.
The signaling complexes of Abi1–Eps8–SOS1 and Vav2–EGFR
activate the conversion of Cdc42–Rac–GDP to Cdc42–Rac–GTP
which is involved in two main routes (one activating and one
inhibiting) through apoptosis. Therefore, to be able to activate or
inhibit apoptotic state of the cell one should focus on the mole-
cules involved in only activating or inhibiting route. Any distur-
bance in the above molecules affects both activating and
inhibiting routes of apoptosis phenotype.
Similar to apoptosis, there is one activating and one inhibiting
route of cell cycle progression. The tumor suppressor protein p53
negatively regulates cell cycle [101]. On the other hand, c-Jun sig-
naling activates cell cycle [85] by inhibiting p53. The large partic-ipation percentages (97.6%) of these signaling molecules in the
linear paths through cell cycle progression show their importance
in agreement with the literature.
It is known that PLCb [102,103] and calcium signaling [104] is
important in mediating actin reorganization. In this case, one
should be very careful in choosing targets to activate or inhibit ac-
tin reorganization because there are no molecules speciﬁc to this
phenotype. Any modiﬁcation can affect other phenotypes; the par-
ticipation percentage of the molecules disturbed should be very
small for the phenotypes other than actin reorganization.
Active Pyk2 and Grb2–EGFR–active Pyk2 activate c-Src convert-
ing to active c-Src–Pyk2 which is involved in STAT1 signaling
through target genes transcription. Most of these highly participat-
ing signaling molecules are among the speciﬁc molecules for this
phenotype of the EGFR network. Therefore it is possible to manip-
ulate EGF-induced genes transcription by disturbing these speciﬁc
molecules since they have small effects on other pathways in the
network.
The analysis of the participation of molecules indicated that ﬁve
signaling molecules are present in all the linear paths through
tumorigenesis and mitogenesis (participation percentage of
100%). This result means that these phenotypes are strictly depen-
dent on these molecules (low robustness). Particularly the com-
plex, active c-Src–Shc is crucial since it is not involved in most of
the linear paths of other phenotypes (speciﬁc to tumorigenesis
and mitogenesis). Shc was shown to be a direct activator of the
tyrosine kinase c-Src in vitro and in vivo [105]. c-Src has activation
effect on tumorigenesis [106,107]. Inhibition of c-Src may have an
anti-cancer effect and several c-Src inhibitors are in development
or in use as anti-cancer drugs [108,109] but it has roles also in
genes transcription phenotype and therefore the complex forma-
tion mechanism of c-Src with Shc should be considered as the
key process in tumor growth. On the other hand, it was proposed
that KDI1 can selectively inhibit proliferation effect of EGFR signal-
ing and might become an anti-cancer drug [110]. However in the
EGFR network KDI1 is also an inhibitor of the phosphorylation of
the dimer of ErbB1 ligand-active EGFR. Since the phosphorylated
complex is one of the hubs of the network KDI may not be selective
inhibitor of tumorigenesis.4. Conclusions
Over the recent years the large-scale signaling networks have
been reconstructed with the rapid increase in genomic data. Here,
we mathematically analyzed the structure of one of the most
important signaling systems, EGFR network, to deﬁne crucial
points for further researches in developing drugs against tumor
cells. Using graph theory, the network diameter of EGFR network
was found as 11 and its mean path length is 4.7 showing its
small-world structure. The results of the graph theoretical analysis
indicate that the connectivity distribution of the signaling mole-
cules in the network has scale-free nature; four hubs (ErbB1 li-
gand-active EGFR, GTP, GDP and Gb/Gc) connect the rest of the
molecules to the network (see Supplementary Figure).
On the other hand computing linear paths from the ligands to
the phenotypes allowed us to observe importance of each molecule
for each phenotype. Known tumor suppressor proteins MKK4 and
p53 were found to be involved in linear paths of inhibiting route
of cell cycle and also in activating route of apoptosis showing their
inhibition power in cell proliferation. Other important molecules
are apoptosis speciﬁc p38 MAPK, MKK3, and MKK6 which can be
activated when apoptosis is the desired mechanism for the cell. Be-
cause of their speciﬁcity to apoptosis (they are involved in more
than 50% of the linear paths through apoptosis and in less than
50% of the linear paths through other phenotypes) any disturbance
S. Durmus Tekir et al. / Journal of Biomedical Informatics 42 (2009) 228–236 235on these molecules affects mainly apoptosis with very little or no
effect on the other phenotypes of EGFR network. In order to end
with tumorigenesis, the EGFR-mediated signal transduction must
pass over ﬁve signaling molecules (ErbB1 ligand-active EGFR,
ATP, KDI1, c-Src, active c-Src–Shc) that are found to have roles in
all linear paths through tumorigenesis. The tumorigenesis speciﬁc
one is only the complex of c-Src–Shc whose inhibitors may be used
in the design of anti-cancer drugs. Instead of inhibiting c-Src, dis-
turbing the complex c-Src–Shc may have more selective effect on
the cancer therapy.
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